These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: CD19+ in intestinal mucosa predict the response to infliximab in Crohn's disease.
    Author: Ferkolj I, Ihan A, Markovic S.
    Journal: Hepatogastroenterology; 2005; 52(64):1128-33. PubMed ID: 16001645.
    Abstract:
    BACKGROUND/AIMS: Infliximab is an effective treatment for Crohn's disease, yet about 30% of patients have a weak or no response. The aim of the study was to determine if the likelihood of a patient achieving complete remission 3 months after treatment with infliximab can be predicted from immunological parameters measured in peripheral blood and inflamed intestinal mucosa before the treatment. METHODOLOGY: 25 patients with Crohn's disease resistant to conventional therapy underwent treatment with infliximab. Samples of peripheral blood and inflamed intestinal mucosa were analyzed by flow-cytometry before infliximab administration. The clinical response was evaluated after 3 months. RESULTS: At 3 months post-treatment, 11 (44%) patients were in complete remission, while 14 (56%) had no remission. Logistic regression analysis revealed that 50% of patients having 2.29% of CD19+ cells in inflamed intestinal mucosa may be expected to achieve complete remission. If the proportion of CD19+ cells in the inflamed mucosa is 5%, the probability of the patient achieving complete remission following treatment rises to 85%. CONCLUSIONS: This is the first study which found that a high percentage of CD19+ cells in the inflamed intestinal mucosa of a patient with Crohn's disease may predict long remission after infliximnab therapy.
    [Abstract] [Full Text] [Related] [New Search]